NeoGenomics (NASDAQ:NEO – Get Free Report) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 0.080-0.100 for the period, compared to the consensus estimate of 0.060. The company issued revenue guidance of $655.0 million-$667.0 million, compared to the consensus revenue estimate of $661.7 million.
NeoGenomics Stock Up 2.3 %
Shares of NeoGenomics stock traded up $0.36 on Thursday, reaching $15.82. The stock had a trading volume of 940,050 shares, compared to its average volume of 820,345. The company has a 50 day moving average price of $14.69 and a 200 day moving average price of $14.73. The company has a quick ratio of 1.93, a current ratio of 2.01 and a debt-to-equity ratio of 0.37. NeoGenomics has a 1 year low of $12.77 and a 1 year high of $21.22. The stock has a market capitalization of $2.03 billion, a P/E ratio of -25.52 and a beta of 1.19.
NeoGenomics (NASDAQ:NEO – Get Free Report) last released its earnings results on Tuesday, November 5th. The medical research company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.04. The company had revenue of $167.80 million during the quarter, compared to analysts’ expectations of $167.00 million. NeoGenomics had a negative net margin of 12.50% and a negative return on equity of 2.72%. NeoGenomics’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same period last year, the business earned ($0.06) EPS. As a group, equities research analysts forecast that NeoGenomics will post -0.21 EPS for the current year.
Wall Street Analyst Weigh In
Read Our Latest Analysis on NEO
About NeoGenomics
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Further Reading
- Five stocks we like better than NeoGenomics
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- Investing In Automotive Stocks
- Breakout Alert: Qualcomm Just Hit The Rally Button
- The 3 Best Blue-Chip Stocks to Buy Now
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.